Related Experiment Video
Updated: Sep 18, 2026
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Longitudinal Performance of Self-Reported ART Adherence Compared With Tenofovir Diphosphate in Dried Blood Spots in
Christopher M Ferraris1,2, Paul A D'Avanzo3, Naomi Fireman Schiavoni4
1New York State Psychiatric Institute, New York, NY, USA.
Background:
Self-reported ART adherence is widely used in resource-limited settings but may not accurately reflect cumulative drug exposure. Few longitudinal studies in sub-Saharan Africa have directly compared self-report with pharmacologic adherence measures, specifically tenofovir diphosphate concentrations (TFV-DP) in dried blood spots (DBS).
Setting:
Observational cohort study conducted in four public-sector ART clinics in Cape Town, South Africa.
Methods:
We analyzed data from 250 adults living with HIV, followed monthly for 13 visits. Participants reported missed ART doses in the prior 30 days and provided DBS for TFV-DP concentration. Longitudinal associations between missed doses and TFV-DP were examined using generalized estimating equations. Receiver operating characteristic (ROC) analyses evaluated the ability of SR to identify low TFV-DP in DBS (<699 fmol/punch). Logistic GEE models assessed the association between self-reported nonadherence and low TFV-DP.
Results:
Most participants were female (78%), median age 34 years (IQR, 27-42). Median TFV-DP concentrations declined with increasing self-reported missed doses: 1206 (IQR, 943-1442), 1009 (IQR, 773-1364), and 859 (IQR, 542-1194) fmol/punch for 0, 1-2, and ≥3 missed doses, respectively. Each additional missed dose was associated with lower TFV-DP concentrations in adjusted models (β = -29.2 fmol/punch per missed dose; p<0.001). Reporting ≥2 missed doses was associated with higher odds of low TFV-DP in longitudinal models (adjusted OR 1.50; p<0.001).
Conclusions:
Self-report missed doses correlated with TFV-DP concentrations over time but lacked sensitivity for detecting low drug exposure. Self-report remains pragmatic but may be optimized when paired with objective biomarkers to identify those at risk for treatment failure.
